Non-neutropenic (n = 148) | Neutropenic (n = 148) | p value | |
---|---|---|---|
Age (median [IQR]) | 55.55 (15.85) | 55.75 (14.12) | 0.91 |
Female (%) | 54 (36.5) | 49 ( 33.1) | 0.63 |
SOFA (median [IQR]) | 8.00 [5.00, 10.00] | 10.00 [7.00, 12.00] | < 0.001 |
Hematopoietic cell transplant (HCT) | 0.07 | ||
No (HCT) | 107 (72.3) | 97 (65.5) | |
Autologous HCT | 12 (8.1) | 25 (16.9) | |
Allogeneic HCT | 29 (19.6) | 26 ( 17.6) | |
Immune defect (ID) | 0.94 | ||
Acute leukemia | 66 (44.6) | 62 (41.9) | |
Chronic leukemia | 2 (1.4) | 6 (4.1) | |
Hodgkin disease | 7 (4.7) | 5 (3.4) | |
Drug-induced immunosuppression | 1 (0.7) | 1 (0.7) | |
Myeloma | 13 (8.8) | 13 (8.8) | |
Non-Hodgkin lymphoma | 31 (20.9) | 32 (21.6) | |
Other | 10 ( 6.8) | 11 (7.4) | |
Solid tumor | 16 (10.8) | 17 (11.5) | |
Systemic | 2 ( 1.4) | 1 (0.7) | |
Kidney comorbidity | 13 ( 8.8) | 9 (6.1) | 0.51 |
Respiratory support | 0.73 | ||
High-flow nasal oxygen | 28 (18.9) | 24 (16.2) | |
Non-invasive ventilation | 13 ( 8.8) | 16 (10.8) | |
O2 | 78 (52.7) | 84 (56.8) | |
Mechanical ventilation | 29 (19.6) | 24 (16.2) | |
Vasopressors | 115 (77.7) | 103 (69.6) | 0.15 |
Renal replacement therapy | 42 (28.4) | 39 (26.4) | 0.79 |
Acute respiratory failure diagnosis | 0.82 | ||
Bacterial | 69 (46.6) | 73 (49.3) | |
Fungal | 15 (10.1) | 16 (10.8) | |
Other | 49 (33.1) | 44 (29.7) | |
Pneumocystis | 1 ( 0.7) | 3 (2.0) | |
Unknown | 14 ( 9.5) | 12 (8.1) | |
No BAL use | 77 (52.0) | 95 (64.2) | 0.05 |
Hospital mortality | 68 (45.9) | 77 (52.0) | 0.35 |